Potential Osteogenesis Imperfecta Treatment Receives Rare Pediatric Disease Designation
source: pixabay.com

Potential Osteogenesis Imperfecta Treatment Receives Rare Pediatric Disease Designation

According to a story from BioSpace, the biopharmaceutical company Mereo BioPharma Group recently announced that its investigational therapy setrusumab has earned Rare Pediatric Disease designation from the US Food and…

Continue Reading Potential Osteogenesis Imperfecta Treatment Receives Rare Pediatric Disease Designation
Company Developing Treatment for Osteogenesis Imperfecta Announces Successful FDA Phase 2 Wrap-up Meeting
source: pixabay.com

Company Developing Treatment for Osteogenesis Imperfecta Announces Successful FDA Phase 2 Wrap-up Meeting

According to a story from Financial Buzz, the biopharmaceutical company Mereo BioPharma Group plc recently announced that it has successfully concluded its Type B End-of-Phase 2 meeting with the US…

Continue Reading Company Developing Treatment for Osteogenesis Imperfecta Announces Successful FDA Phase 2 Wrap-up Meeting

This Just In: Patient Reported Experiences are Important for Research in Osteogenesis Imperfecta

What is osteogenesis imperfecta? Osteogenesis imperfecta (OI) actually refers to a group of four distinct rare disorders- OI Type I, II, III, and IV. They're all characterized by brittle bones which…

Continue Reading This Just In: Patient Reported Experiences are Important for Research in Osteogenesis Imperfecta